Cynata Therapeutics advance to second cohort in stem cell trial – Small Caps
Small Caps |
Cynata Therapeutics advance to second cohort in stem cell trial
Small Caps Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has received an encouraging early response from the clinical trials of its stem cell product CYP-001, which began in November to treat steroid-resistant graft-versus-host … Encouraging Early Safety and Efficacy Data in Cynata's Phase 1 Trial of CYP-001 in GvHD; DSMB Recommendation to … HC Wainright repeats 'buy' on Cynata as ongoing trial is cleared by data safety monitoring board |
